

# RenÃ©-Olivier Casanovas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2948797/publications.pdf>

Version: 2024-02-01

88  
papers

6,633  
citations

126858

33  
h-index

69214

77  
g-index

89  
all docs

89  
docs citations

89  
times ranked

6079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2011, 377, 42-51.	6.3	957
2	Early Positron Emission Tomography Response—Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	0.8	397
3	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	13.9	313
4	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	0.8	313
5	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1858-1867.	6.3	311
6	Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008, 26, 2512-2518.	0.8	301
7	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 37-43.	0.6	280
8	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	13.9	264
9	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	0.8	231
10	Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. <i>Blood</i> , 2009, 113, 2765-3775.	0.6	224
11	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology, the</i> , 2020, 7, e511-e522.	2.2	201
12	No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2568-2574.	0.8	199
13	Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1735-1743.	3.3	152
14	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	9.4	151
15	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	0.8	148
16	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology, The</i> , 2019, 20, 202-215.	5.1	145
17	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	13.5	138
18	Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5980-5987.	0.8	137

#	ARTICLE	IF	CITATIONS
19	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	0.6	135
20	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	0.6	130
21	Management and outcome of primary CNS lymphoma in the modern era. <i>Neurology</i> , 2020, 94, e1027-e1039.	1.5	125
22	Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. <i>Blood Advances</i> , 2018, 2, 807-816.	2.5	107
23	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015, 2, e160-e165.	2.2	95
24	Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0140830.	1.1	90
25	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	0.8	90
26	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	1.7	84
27	Interim <sup>18</sup> F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 569-573.	2.8	76
28	Deep-Learning <sup>18</sup> F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 30-36.	2.8	75
29	Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1362-1370.	3.3	70
30	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	0.6	60
31	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
32	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
33	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021, 39, 1203-1213.	0.8	39
34	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	0.8	37
35	Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from Lymphoma Study Association (LYSA) centers. <i>American Journal of Hematology</i> , 2018, 93, 729-735.	2.0	31
36	Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?. <i>Blood</i> , 2017, 129, 3059-3070.	0.6	30

#	ARTICLE	IF	CITATIONS
37	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	1.3	29
38	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	27
39	Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 193-199.	1.2	25
40	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	2.2	21
41	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. <i>Blood Advances</i> , 2021, 5, 2438-2446.	2.5	20
42	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1463-1464.	3.3	19
43	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. <i>Blood</i> , 2022, 139, 2338-2346.	0.6	18
44	Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011). <i>Journal of Clinical Oncology</i> , 2021, 39, 3251-3260.	0.8	17
45	Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma. <i>Haematologica</i> , 2022, 107, 221-230.	1.7	17
46	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019, 33, 776-780.	3.3	16
47	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020, 4, 3217-3223.	2.5	16
48	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	1.2	15
49	The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. <i>Blood Advances</i> , 2021, 5, 1991-2002.	2.5	15
50	Low Suvmax Measured on Baseline FDG-PET/CT and Elevated Î²2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies. <i>Blood</i> , 2016, 128, 1101-1101.	0.6	14
51	Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1632-1632.	0.6	13
52	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016, 128, 471-471.	0.6	12
53	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	1.3	12
54	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1091-1101.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. <i>Diagnostics</i> , 2022, 12, 417.	1.3	9
56	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	2.5	8
57	Shaping for PET image analysis. <i>Pattern Recognition Letters</i> , 2020, 131, 307-313.	2.6	7
58	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	1.7	7
59	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 335-335.	0.6	6
60	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	5
61	Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). <i>Blood</i> , 2019, 134, 2832-2832.	0.6	5
62	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. <i>Blood</i> , 2011, 118, 2632-2632.	0.6	5
63	Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers. <i>Blood</i> , 2016, 128, 3450-3450.	0.6	5
64	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 755623.	2.2	5
65	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. <i>Blood Advances</i> , 2022, 6, 6169-6179.	2.5	5
66	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4202-4202.	0.6	4
67	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019, 134, 1524-1524.	0.6	3
68	CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria. <i>Blood</i> , 2019, 134, 2887-2887.	0.6	3
69	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	0.8	2
70	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. <i>Blood</i> , 2016, 128, 184-184.	0.6	2
71	Interim [18F]Fluorodeoxyglucose Positron Emission Tomography SUVmax Reduction Is Superior to Visual Analysis to Predict Early patient's Outcome In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 320-320.	0.6	2
72	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Reply to M. Lambertini et al. Journal of Clinical Oncology, 2017, 35, 805-806.	0.8	1
74	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). Journal of Physical Education and Sports Management, 2021, 7, a005934.	0.5	1
75	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. Blood, 2019, 134, 5333-5333.	0.6	1
76	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. Blood, 2014, 124, 1625-1625.	0.6	1
77	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. Cancers, 2022, 14, 2532.	1.7	1
78	De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkinâ€™s lymphoma. International Journal of Clinical Pharmacy, 2015, 37, 1033-1037.	1.0	0
79	Evaluation of the Prognostic Value of CD45RO+ and FOXP3+ Cells of the Micro-Environment In Classical Hodgkin Lymphomas Using Tissue Micro Array. Blood, 2010, 116, 2687-2687.	0.6	0
80	Prognostic Role of Host Immune Gene Polymorphisms for Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in the GELA (Groupe) Tj ETQq0,0,0 rgBT /Overlock 1 3676-3676.	0.6	0
81	FCGR3A and FCGR2A Polymorphisms Do Not Affect Response and Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab and Chemotherapy. A Study Based on 554 Patients Included in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Prospective Multicentric Study LNH2003. Blood, 2011, 118, 90-90.	0.6	0
82	Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL). Blood, 2011, 118, 2673-2673.	0.6	0
83	Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study. Blood, 2014, 124, 4430-4430.	0.6	0
84	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. Blood, 2015, 126, 3919-3919.	0.6	0
85	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	0.6	0
86	Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study). Blood, 2019, 134, 2765-2765.	0.6	0
87	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. Cancers, 2022, 14, 1761.	1.7	0
88	Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature. CNS Oncology, 0, , .	1.2	0